First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian C...
17 January 2019 - 11:05PM
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology
corporation, today announced that the first patient has been
treated in the Phase 1 trial evaluating neoepitopes formulated in
the Company’s proprietary DPX delivery platform in patients with
ovarian cancer. The study is part of the Company’s DPX-NEO program,
which is an ongoing collaboration between UConn Health and IMV to
develop neoepitope-based anti-cancer therapies.
“Expanding our DPX-based clinical immunotherapy
program beyond DPX-Survivac is an important milestone for IMV, and
we are pleased to be able to do so with this type of cutting-edge
program in which the novel mechanism of action underscoring all
DPX-based candidates plays a critical role,” said Frederic Ors,
Chief Executive Officer at IMV. “We believe that the potential of
neoepitope-based therapies could be a significant advance in the
way physicians treat patients with ovarian cancer who today face a
high unmet medical need. We look forward to working with UConn
Health to advance this program as IMV is committed to developing an
immunotherapy option for women affected by this disease.”
Investigators will assess the safety and
efficacy of using patient-specific neoepitopes discovered at UConn
Health and formulated in IMV’s proprietary DPX-based delivery
technology in women with ovarian cancer. Investigators plan to
enroll up to 15 patients in the Phase 1 study. UConn Health is
funding the trial with IMV providing materials and counsel.
Epitopes are the part of the biological molecule
that is the target of an immune response. Neoepitopes are the
mutated proteins produced by a patient's own tumors. Neoepitope
immunotherapies target these patient-specific proteins and have
been referred to as ‘the next immunotherapy frontier.’ (1)
“The first immunization of the first ovarian cancer patient with
our personalized, patient-specific neoepitopes developed at the
University of Connecticut using our proprietary technology,
formulated in IMV’s excellent immunomodulatory DPX delivery
platform, is a major milestone for us,” said Study Investigator
Pramod K Srivastava, PhD, MD, Director of the Neag Comprehensive
Cancer Center at the University of Connecticut School of
Medicine.
About the DPX-NEO Program
The DPX-NEO program is an ongoing collaboration
evaluating the anti-cancer activity of proprietary patient-specific
epitopes developed at UConn Health and formulated in IMV’s
DPX-based novel immunotherapeutic delivery technology. IMV had
previously announced the results from preclinical research in which
researchers at UConn found that neoepitopes formulated in DPX-based
formulations demonstrated superior immunogenic activity over
comparators in mouse tumor models. In addition, IMV also previously
announced a breakthrough in formulating multiple peptides in DPX
formulations. The Company has patented the technology, which allows
for both a larger number and a broader potential range of peptides
into a single formulation as compared to standard formulation
technologies.
About IMV
IMV Inc. is a clinical stage biopharmaceutical
company dedicated to making immunotherapy more effective, more
broadly applicable, and more widely available to people facing
cancer and other serious diseases. IMV is pioneering a new class of
immunotherapies based on the Company’s proprietary drug delivery
platform. This patented technology leverages a novel mechanism of
action that enables the programming of immune cells in
vivo, which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a
T cell-activating immunotherapy that combines the utility of the
platform with a target: survivin. IMV is currently assessing
DPX-Survivac as a monotherapy in advanced ovarian cancer, as well
as a combination therapy in multiple clinical studies with Incyte
and Merck. Connect at www.imv-inc.com.
IMV Forward-Looking
Statements
This press release contains forward-looking
information under applicable securities law. All information that
addresses activities or developments that we expect to occur in the
future is forward-looking information. Forward-looking statements
are based on the estimates and opinions of management on the date
the statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. IMV Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law. These forward-looking statements
involve known and unknown risks and uncertainties and those risks
and uncertainties include, but are not limited to, our ability to
access capital, the successful and timely completion of clinical
trials, the receipt of all regulatory approvals and other risks
detailed from time to time in our ongoing quarterly filings and
annual information form Investors are cautioned not to rely on
these forward-looking statements and are encouraged to read IMV’s
continuous disclosure documents, including its current annual
information form, as well as its audited annual consolidated
financial statements which are available on SEDAR
at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
Contacts for IMV:
MEDIA Andrea Cohen, Sam Brown
Inc.T: (917) 209-7163 E: AndreaCohen@sambrown.com
INVESTOR RELATIONSMarc Jasmin, IMV
Senior Director, Investor RelationsT: (902) 492-1819 E:
info@imv-inc.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
REFERENCES1 Neoepitope Vaccines, Next
Immunotherapy Frontier Cancer Discovery Published Online
First December 28, 2015;
doi:10.1158/2159-8290.CD-NB2015-179
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024